First-line trifluridine/tipiracil plus bevacizumab offered a slight survival benefit over capecitabine plus bevacizumab in patients with unresectable metastatic colorectal cancer in the TASCO1 trial.
Medscape Medical News
Jury’s Still Out on Trifluridine/Tipiracil Plus Bev in mCRC
